argenx SE
argenx SE
- Market cap
- $59.19B
- P/E ratio
- 44.34
Your view on ARGX
Overview
What the company does, where it operates, and who runs it.
About argenx SE
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Timothy Van Hauwermeiren EMBA,
- Headquarters
- Laarderhoogtweg 25, Amsterdam, NL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Timothy Van Hauwermeiren EMBA,
- Headquarters
- Laarderhoogtweg 25, Amsterdam, NL
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB.
The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V.
, VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services.
argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for argenx SE from FRC's valuation model, read against the market price. ARGX last traded at $941.25, 44.3× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for argenx SE. Starting points for argenx SE: P/E 44.3, EPS $21.16, beta -0.02 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for argenx SE. Trailing twelve-month EPS for argenx SE stands at $21.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$1,143.94
average of 18 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy16
- Hold2
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2018 | Next QtrJun 2019 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | −$1.49 | −$0.63 | $28.35 | $37.13 |
| Low estimate | −$1.78 | −$0.76 | $27.15 | $31.67 |
| High estimate | −$1.19 | −$0.51 | $32.12 | $43.77 |
| No. of analysts | 12 | 11 | 9 | 9 |
| Year-ago EPS | — | — | $19.631 | — |
| Growth | — | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2018 | Next QtrJun 2019 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $82.15M | $6.98M | $6.42B | $8.11B |
| Low estimate | $65.72M | $5.58M | $6.27B | $7.60B |
| High estimate | $98.58M | $8.37M | $6.51B | $8.48B |
| No. of analysts | 12 | 11 | 14 | 12 |
| Year-ago revenue | — | — | $4.15B | — |
| Growth | — | — | +54.5% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for argenx SE. argenx SE has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AMGNAmgen Inc. | Healthcare | Drug Manufacturers - General | $240.1B | ||
| BIIBBiogen Inc. | Healthcare | Drug Manufacturers - General | $37.2B | ||
| INCYIncyte Corporation | Healthcare | Biotechnology | $24.0B | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PSYBFPsyBio Therapeutics Corp. | Healthcare | OTC | $1,275 | ||
| PTCHFPureTech Health plc | Healthcare | OTC | $410.4M | ||
| PTCTPTC Therapeutics, Inc. | Healthcare | NASDAQ | $5.0B | ||
| PTGXProtagonist Therapeutics, Inc. | Healthcare | NASDAQ | $8.3B | ||
| PTHSPelthos Therapeutics Inc. | Healthcare | AMEX | $27.9M | ||
| PTIXProtagenic Therapeutics, Inc. | Healthcare | NASDAQ | $470,654 | ||
| PTNPalatin Technologies, Inc. | Healthcare | NASDAQ | $9.2M | ||
| PTX.AXPrescient Therapeutics Limited | Healthcare | ASX | — | ||
| PULMPulmatrix, Inc. | Healthcare | NASDAQ | $4.9M | ||
| PVCTProvectus Biopharmaceuticals, Inc. | Healthcare | OTC | $18.7M | ||
| PVLAPalvella Therapeutics, Inc. | Healthcare | NASDAQ | $2.1B | ||
| PXMDPaxMedica, Inc. Common Stock | Healthcare | OTC | $37,879 | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| IBBiShares Biotechnology ETF | $11.1B in assets | 3.76% | |
| CGGOCapital Group Global Growth Equity ETF | $11.5B in assets | 1.06% | |
| FBTFirst Trust NYSE Arca Biotechnology Index Fund | $3.0B in assets | 3.79% | |
| AVDEAvantis International Equity ETF | $19.3B in assets | 0.16% | |
| FDGAmerican Century Focused Dynamic Growth ETFAmerican Century Focused Dynamic Growth ETFAmerican Century Focused Dynamic Growth ETF | $412M in assets | 1.34% | |
| TGRTT. Rowe Price Growth ETF | $1.6B in assets | 0.57% | |
| FTQIFirst Trust Nasdaq BuyWrite Income ETF | $954M in assets | 0.53% | |
| TOUST. Rowe Price International Equity ETF | $1.7B in assets | 0.45% | |
Largest holders first, then the funds most concentrated in ARGX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold argenx SE, and how their positions are changing. At a $59.19B market value, institutional positions materially move argenx SE's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming argenx SE. argenx SE is a $59.19B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming argenx SE. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for argenx SE. Coverage tracks argenx SE within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of argenx SE.